WO2001085206A2 - Compositions immunosuppressives - Google Patents

Compositions immunosuppressives Download PDF

Info

Publication number
WO2001085206A2
WO2001085206A2 PCT/US2001/014718 US0114718W WO0185206A2 WO 2001085206 A2 WO2001085206 A2 WO 2001085206A2 US 0114718 W US0114718 W US 0114718W WO 0185206 A2 WO0185206 A2 WO 0185206A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ginkgolide
immunophilin
gingkolide
composition
Prior art date
Application number
PCT/US2001/014718
Other languages
English (en)
Other versions
WO2001085206A3 (fr
Inventor
David Haines
Arpad Tosaki
Fadia F. Mahmoud
Original Assignee
David Haines
Arpad Tosaki
Mahmoud Fadia F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Haines, Arpad Tosaki, Mahmoud Fadia F filed Critical David Haines
Priority to EP01935128A priority Critical patent/EP1299119A2/fr
Priority to AU2001261248A priority patent/AU2001261248A1/en
Priority to JP2001581859A priority patent/JP2004510694A/ja
Priority to CA002408889A priority patent/CA2408889A1/fr
Priority to US10/275,996 priority patent/US20040091477A1/en
Publication of WO2001085206A2 publication Critical patent/WO2001085206A2/fr
Publication of WO2001085206A3 publication Critical patent/WO2001085206A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to immunosuppression.
  • Immunosuppressants such as cyclosporin A (CsA) and FK-506 have been used clinically to inhibit rejection of transplanted organs and to treat autoimmune diseases. In many cases, transplant recipients and individuals suffering from autoimmune diseases require long term immunosuppression. High toxicity profiles of immunosuppressants such as CsA and FK506 limit their clinical benefit. Side effects include nephrotoxicity, hypertension, increased risk of diabetes, and neurological toxicity.
  • the invention features immunosuppressive compositions with reduced adverse side effects.
  • the immunosuppressive composition contains an immunophilin-binding agent such as a calcineurin inhibitor and a ginkgolide.
  • the gingkolide composition preferably contains an antioxidant or free radical scavenger. More preferably, the gingolide contains platelet activating factor receptor (PAFR) antagonist activity. Most preferably, the composition contains PAFR antagonist activity and at least two antioxidants.
  • the composition contains a cyclic AMP phosphodiesterase inhibitor.
  • the gingkolide composition has the following activities: cAMP phophosdiesterase inhibitory activity, PAFR receptor antagonist activity, and antioxidant or free radical scavenging activity.
  • a free radical scavenger is a composition which reduces the level of free radicals.
  • a free radical scavenger reduces the level of oxygen radical which contribute to oxidative stress.
  • the level of free radicals is reduced by direct scavenging of free radicals or by inducing the production of a composition with a scavenging effect on free radicals.
  • a phosphodiesterase inhibitor is a composition, which inhibits or selectively reduces the activity of a phosphodiesterase enzyme.
  • the compound inhibits the enzymatic activity of a cAMP-specific phosphodiesterase.
  • the compound inhibits type III phosphodiesterases or type IN phospodiesterases.
  • a PAFR antagonist is a compound which inhibits binding of PAF (l-0-alkyl-2-acetyl-sn-glycerol-3 -phosphorylcholine) to its receptor.
  • PAF is a potent inflammatory phospholipid mediator, and inhibition of PAF binding to PAFR, e.g., by a PAFR antagonist, reduces inflammation.
  • Immunophilin-binding compositions include rapamycin or an analog thereof and calcineurin inhibitors such as FK506 and Cyclosporin A (CsA) or an analog thereof.
  • the invention also includes a method of inducing immunosuppression (e.g., inhibiting activation of an immune cell such as a T cell or a B cell) in a mammal.
  • the method is carried out by coadministering of an immunophilin-binding compound such as a calcineurin inhibitor and a gingkolide in such amounts so as to provide a synergistic immunosuppressive effect.
  • the gingkolide is administered at a dose that preferentially inhibits T-cell activation.
  • the immunophilin-binding compound e.g., a calcineurin inhibitor
  • the gingkolide is first administered followed by the immunophilin-binding compound.
  • the immunophilin-binding compound is administered first and then the gingkolide.
  • Such a coadministration regimen is useful to inhibit rejection of an allografted tissue in a mammal.
  • a calcineurin inhibitor and a gingkolide are administered prior to or after transplantation of an allogeneic tissue.
  • a method of inhibiting activation of an immune cell is carried out by contacting an immune cell with an immunophilin-binding compound and a gingkolide compound.
  • the ginkgolide compound is selected from the group consisting of a phosphodiesterase inhibitor, a platelet activating factor (PAFR) antagonist, and a free radical scavenger.
  • Therapeutic methods include a method of inhibiting rejection of an allograft in a mammal; a method of inhibiting cardiac hypertrophy in a mammal; a method of reducing a symptom, e.g., chronic inflammation, of an autoimmune disease; and a method of reducing a symptom of asthma.
  • a method of suppressing an immune response in a mammal is carried out by administering to the mammal an effective amount for inducing a synergistic immunosuppression of an immunophilin-binding compound and a gingkolide compound.
  • the compounds are administerd simultaneously or sequentially, by the same or different routes.
  • a method of identifying an immunosuppressive agent is carried out by contacting an immune cell population with candidate ginkgolide compound and measuring T cell activation.
  • a decrease in T cell activation in the presence of the compound compared to the level in the absence of the compound indicates that the compound is an immunosuppressive agent.
  • T cell activation is measured by detecting cell surface CD25 expression, or production of a cytokine such as IL-2.
  • the following steps are carried out: (a) contacting an immune cell with an immunophilin-binding compound; (b) contacting an immune cell with a candidate ginkgolide compound; (c) contacting an immune cell with both an immunophilin- binding compound and a candidate ginkgolide compound; and (d) measuring T cell activation.
  • a greater than additive decrease in T cell activation detected in the cell culture in step (c) compared to that detected in the cell cultures of (a) and (b) indicates that the ginkgolide and immunophilin-binding compound tested are synergistically immunosuppressive.
  • Fig. 1 is a bar graph showing in vitro cytokine expression responses by PBMC from asthmatic subjects. Expression of interleukins 4 and 5 by activated, or non-activated human PBMC, to CsA and BN52021 were measured. Cells were cultured with media (solid columns), 20 nM PMA + 1.0 ⁇ M ionomycin (PMA/I) (dark hatched columns), 1.0 ⁇ M CsA + PMA/I (grey columns), or l ⁇ M BN52021 + PMA/I (light hatched columns).
  • media solid columns
  • PMA/I 1.0 ⁇ M ionomycin
  • CsA + PMA/I grey columns
  • l ⁇ M BN52021 + PMA/I light hatched columns.
  • Concentrations of IL-4 and IL-5 were determined in culture supernatants by antibody capture ELISA and expressed in pg/ml. Activated cells responded to CsA treatment by suppression of both cytokines, with a trend toward suppression resulting from treatment with BN52021.
  • Fig. 2 is a bar graph showing in vitro expression of lymphocyte activation markers in PBMC from asthma patients. Expression of lymphocyte surface activation markers by activated or nonactivated human PBMC was measured. Cells were stimulated with media (solid columns), 20 nM PMA + 1.0 ⁇ M ionomycin (PMA/I) (dark hatched columns), 1.0 ⁇ M CsA + PMA/I (grey columns), or 1 ⁇ M BN52021 + PMA/I (light hatched columns). After 24 hours flow cytometric analysis was conducted for expression of CD25, CD45RA, CD54 and HLA-DR. Results are representative of 3 independent assays and are expressed as the percentage of lymphocytes in each sample expressing a particular surface antigen.
  • Fig. 3A is a bar graph showing the incidence of total (reversible and irreversible) reperfusion-induced ventricular fibrillation (NF) (open columns) and incidence of irreversible NF (solid columns) relative to dose of FK506.
  • Fig. 3B is a bar graph showing the incidence of ventricular tachycardia (NT).
  • Fig. 4A is a bar graph showing the incidence of total (reversible and irreversible) reperfusion-induced ventricular fibrillation (NF) (open columns) and incidence of irreversible NF (solid columns) relative to dose of FK506 and Egb761.
  • compositions described herein are useful to prevent rejection of transplanted organs, prevent cardiac hypertrophy, and improve the clinical prognosis for patients suffering from ischemic heart disease
  • compositions are also useful to treat autoimmune diseases.
  • a macrolide immunosuppressant such as FK506
  • one or more components of a Ginkgo biloba extract allows a lower dose of the macrolide immunosuppressant than that required to achieve immunsuppression in the absence of a gingkolide.
  • IL-2 is an important messenger in the signal transduction pathway that leads to the stimulation and proliferation of T-cells. Once a T-cell is activated, a series of signals in the cytoplasm and nucleus leads to the production of IL-2 and IL-2 receptors. One of the steps in the signal transduction cascade is the activation of the transcription factor nuclear factor of activated T-cells (NFAT) by calcineurin.
  • NFAT transcription factor nuclear factor of activated T-cells
  • the immunosuppressive agents described herein inhibit T cell activation.
  • Calcineurin inhibitors include FK506 (Tacrolimus), L-732,531(a semi-synthetic analog of FK506), FK 520, L-683, 590 (an analog of FK506), L-685,818 (a C18-hydroxy, C21 -ethyl derivative of FK506), L-732,531 (an analog of FK506 containing a hydroxyethylindole substituent), 9-deoxo-31 -O-demethyl FK506, 31 -O-demethyl FK506, FK1012, Ascomycin (a class of anti-inflammatory macrolactams), A-l 19435 (a less nephrotoxic analog of ascomycin with 10X higher therapeutic index), SDZ ASM 981 (an ascomycin derivative), indolyl-ASC,
  • tether C32-0-arylethyl ether
  • C24-deoxyascomycin ABT-281
  • AKAP79 an analoge which inhibits calcineurin through a site distinct from immunophilin- binding region
  • tyrphostins A8 also designated AGIO
  • tyrphostins A23 also designated AG18
  • tyrphostins A48 also designated AG112 Cyclosporin A and analogs
  • Cyclosporin A is produced as a metabolite by the fungus species Tolypocladium inflatum Gams. Chemically, cyclosporin A is designated as [R-[R,R-(E)]]-cyclic-(L-alanyl- D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucy l-N-methyl-L-valyl-3-hydroxyN,4-dimethyl- L-2-amino-6-octenoyl-L-a-amino-but ⁇ -yl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N- methyl-L-leucyl).
  • Cyclosporin A is commercially available in oral dosage form or intravenous dosage form Cyclosporin forms a complex with cyclophilin in the cytoplasm, which then binds to calcineurin, a calcium- and calmodulin-dependent phosphatase, in a calcium-dependent manner. Inhibition of calcineurin activity is implicated in the activation and/or translocation of NFAT which binds to an IL-2 enhancer allowing the interleukin-2 gene to be transcribed. The transcription of several other cytokines, including interferon- gamma, and several other interleukins, is also inhibited by CsA.
  • CsA is toxic at levels necessary to mediate posttransplant graft acceptance.
  • the primary adverse effect is renal toxicity.
  • increases in renal vascular resistance, decreased Na+ urinary excretion and other indicators of renal stress were significant after dosages of 4 and 5 mg/kg in human subjects (Butterly et al., 1995, Kidney International 48:337-343).
  • Specific suppression of T lymphocyte activation was only observed following at or above 5 mg kg (De Nicola et al., 1995, Nephrology, Dialysis, Transplantation 10:1739- 44). In order to achieve immunosuppression, generally toxic doses of CsA must be used.
  • a immunosuppressive treatment program in which an immunophilin-binding immunosuppressive agent such as CsA or FK506 is coadministered with a gingkolide allows post transplant immunosuppression to be achieved at dosages of immunophilin-binding durg which is 3-5 times less than are currently used (i.e., in the absence of the gingkolide).
  • the combination of ginkgolides plus calcineurin inhibitors counteracts vasoconstriction and postoperative reperfusion injury, which are known side effects of immunophilin-binding immunosuppressive agents.
  • the combination therapy approach is useful to augment current therapeutic approaches to post-operative reperfusion injury of major organ systems.
  • Cyclosporine A and related compounds include (gamma-OH) MeLeu(4)-Cs (211- 810), D-Sar (alpha-SMe)(3) Val(2)-DH-Cs (209-825), Cyclosporin G (Norvaline is substituted for alpha-aminobutyric acid at the 2 position), A238L (a viral protein from African swine fever virus acts like cyclosporin A), SDZ 211-811, Cain ( a 240-kDa endogenous cytoplasmic protein), PD 144795 (a calcineurin-inhibitor with anti-HIN properties), sodium orthovanadate, SDZ ASM 981, cyclolinopeptide A (CLA; cyclic hydrophobic nonapeptide present in linseed), A457-482 (an autoinhibitory peptide of calcineurin), and Cypermethrin. FK506 and analogs
  • the macrocyclic immunosuppressant FK506 (tacrolimus) is calcineurin inhibitor that has been used clinically in organ transplant surgery and for the treatment of psoriasis and rheumatoid arthritis.
  • FK506 enters the cytoplasm of cells and forms a complex with the immunophilin FK-binding protein-12 (FKBP-12).
  • FKBP-12 immunophilin FK-binding protein-12
  • the protein-drug complex prevents calcineurin, a calcium and calmodulin-dependent phosphatase, from producing ⁇ FAT, thereby inhibiting IL-2 production.
  • Rapamycin and analogs Rapamycin is a macrocyclic compound related to the immunosuppressant FK506.
  • Rapamycin like FK506, binds to FKBP-12 in the cytosol of T-cells, however, rapamycin inhibits the proliferation of T-cells through a different mechanism and at a different point in the signal transduction pathway of T-cells.
  • the rapamycin-FKBP-12 complex interfers with the signal transduction pathway at the point by blocking IL-2 induced activation of p70 S6 kinase. The complex then prevents the phosphorylation of ribosomal S6, thereby preventing T-cell proliferation.
  • a complex of a drug e.g., CsA, FK506, rapamycin, and derivatives thereof
  • an immunophilin e.g, and FKBP
  • the drug can not act alone, nor can the immunophilin.
  • formation of a CsA/cyclophilin complex causes CsA to undergo a conformational change leading to exposure of hydrophobic regions of CsA.
  • the hydrophobic regions bind to and inhibit calcineurin.
  • FK506 and rapamycin are similar to CsA in this respect.
  • Each of these drugs contain two distinct protein binding regions that enable them to bind both to their corresponding immunophilin and the specific signal protein on which they act.
  • Ginkgo Biloba L. is a plant, the leaves, roots, and fruit of which have been used for medicinal purposes for centuries. Extracts of various parts of the plant are commercially available.
  • a gingkolide is a Ginkgo biloba extract, synthetic derivative thereof, or purified component thereof.
  • a gingkolide preferably contains one or more immunologically active components such as an antioxidant component, a PAFR antagonist component, or a phosphodiesterase inhibitory component.
  • an extract is made from gingko leaves and used at a concentration that contains about 24- 25% ginkgo-flavone-glycosides.
  • the extract may also contain terpenoids such as Egb761 or LI- 1370.
  • the preparation contains 24% ginkgo-flavone glycosides and 6% terpenoids.
  • the ginkgo-flavone glycosides are sometimes referred to as heterosides.
  • EGb761 is a commercially available leaf extract of Ginkgo biloba, containing: GA, GB, GC, GJ, GM and bilobalide.
  • a ginkgolide compound is purified when it is removed from the substances with which it naturally occurs.
  • a purified ginkgolide compound is at least 85% of the composition by weight.
  • the component is at least 90%, 95%, 99%, or 100% of the composition.
  • Naturally-occurring Ginkgo biloba contains: (A) biflavones such as amentoflavone, bilobetin, sequoiaflavone, ginkgetin, isoginkgetin, Sciadopitysin; (B) flavonol glycosides; (C) terpene trilactones, such as Gingkolide A, GingkolideB, GingkolideC, GingkolikeJ, GingkolideM and bilobalide; (D) rutin; (E) quercetin; and (F) a 30 kDa Ginkgo biloba glycoprotein, which reacts with antiserum against beta l- 2 xylose-containing N-glycans.
  • biflavones such as amentoflavone, bilobetin, sequoiaflavone, ginkgetin, isoginkgetin, Sciadopitysin
  • B flavon
  • Ginkgolide A is a leaf extract containsin terpene trilactone. This gingkolide is a PAFR antagonist, but has no apparent antioxidant properties. It is also known as BN52020, CAS 15291-75-5.
  • Ginkgolide B is a leaf extract containing terpene trilactone. It is a PAFR antagonist, with antioxidant properties and may be referred to as BN52021 or CAS 15291-77-7.
  • GC ginkgolide C: a terpene trilactone, leaf extract. A PAFR antagonist, with antioxidant properties.
  • Ginkgolide J is a leaf extract containing terpene trilactone with PAFR antagonist activity and antioxidant properties.
  • Ginkgolide M GM
  • This gingkolide has PAFR antagonist activity and antioxidant properties.
  • Bilobalide a sesquiterpene trilactone
  • Ginkgo biloba extract (EGb 761) is a clinically safe, nontoxic, and easily-produced product with a wide range of applications.
  • a synthetic gingkolide compound, hetrazepine derivative BN 50730 (Guinot, P., 1994, Clinical Reviews in Allergy 12, 397-417; U.S. Patent No.
  • the gingkolide compositions to be administered are in a form which maximizes ginkgolide bioavailability:
  • the composition is a variation of EGb 761 containing 27% ginkgo-flavonol glycosides, 7% terpene lactones. This composition has been shown to extend bioavailability of pharmacologically active ginkgolide components (Li et al, 1997, Planta Medica. 63:563-5.
  • PAFR antagonist activity is measured using known methods, e.g., a biological assay used to evaluate the ability of a compound to inhibit the enzyme 5-lipoxygenase.
  • a biological assay used to evaluate the ability of a compound to inhibit the enzyme 5-lipoxygenase.
  • arachidonic acid is topically applied to a mouse ear.
  • arachidonic acid is converted by 5-lipoxygenase to various leukotrienes, which induce changes in blood flow, erythema, and increase vasodilation and vasopermeability.
  • a candidate PAFR antagonist is similarly administered.
  • the resulting edema is measured by comparing the thickness of the treated ear to a control ear (in the absence of a candidate compound). Reduction of the the edematous response in the presence of the compound indicates that the compound has PAFR antagonist activity.
  • Other assays include those described by Gozal et al, 1998, Am. J. Physiol. 275 (2 Pt 2):R60
  • Phosphodiesterase activity is measured and inhibitors of cAMP-specific phosphodiesterases are identified using methods known in the art, e.g., Bardelle et al., 1999, Anal. Biochem. 275:148-55.
  • Oxygen free radical scavenging/antioxidant activity is also measured using methods known in the art, e.g., the method of Burits et al., 2001, Phytother. Res. 15:103-8.
  • BN52021 has both PAFR antagonist activity and antioxidant activity, but does not possess cAMP phophodiesterase activity.
  • Egb 761 posesses cAMP phophordiesterase inhibitory activity, PAFR antagonist activity, as well as free radical scavenging (antioxidant) activity.
  • Gingkolide biflavonoid compositions
  • Biflavones or biflavonoid compounds are polyphenolic compounds found in vascular plants. These compounds have analgesic properties and are useful as anti-inflammatories.
  • Amentoflavone has antifungal and antiviral effects (including activity against HIV). It has been shown not to internalize into the cell and remains associated with the membrane, where it contributes to membrane stability. Amentoflavone, like caffeine, causes a concentration-dependent increase in Ca2+ release from the heavy fraction of fragmented sarcoplasmic reticulum of rabbit skeletal muscle. The Ca2+ -releasing activity of amentoflavone was approximately 20 times more potent than that of caffeine. It is an anti- inflammatory, found to inhibit cyclooxygenase (from guinea-pig epidermis) without affecting lipoxygenase. This biflavonoid inhibits group II phospholipase A2 (PLA-2) activity.
  • PKA-2 group II phospholipase A2
  • Bilobetin inhibits PLA-2, in turn inhibiting the production of TNFalpha, iNOS, and inducible cyclooxygenase (COX-2). Yet another gingko-derived biflavonoid is sequoiaflavone. Ginkgetin inhibits PLA-2, in turn inhibiting the production of
  • TNFalpha TNFalpha
  • iNOS inducible cyclooxygenase
  • COX-2 inducible cyclooxygenase
  • gingkolide biflavonoids include isoginkgetin, sciadopitysin, rutin, and quercetin
  • Ginkgolide biflavonoids are inhibitors of cAMP-phosphodiesterase.
  • Ginkgolide biflavonoids have been shown to have a cardioprotective effect.
  • the influence of the main flavonoids from Crataegus species (hawthorn, Rosaceae) on coronary flow, heart rate and left ventricular pressure was investigated. Cardioprotective effects were observed with treatment of O-glycosides luteolin-7-glucoside (186%), hyperoside ⁇ 66%) and rutin ⁇ 66%).
  • the data showed an inhibition of the 3',5'-cyclic adenosine monophosphate phosphodiesterase and suggest an inhibition of this enzyme is a mechanism of cardioprotection of flavonoids (Schussler et al. 1995, Arzneisch-Forschung 45:842-5).
  • BN52021 does not have cAMP phosphodiesterase inhibitory activity.
  • BN52021 does not contain the biflavonoids, bilotetin and gikgetin, which are present id EGb 761.
  • Inhibition of PLA-2, TNFalpha, COX-2 and iNOS contribute to immune suppressive effect of biflavonoid-containing gingkolides, e.g.,. EGb 761.
  • BN52021 does not contain biflavonoids Immunosuppressive drug combinations
  • the dose-response curve of a calcinerin inhibitor e.g., FK506, was found to be favorably altered in the presence of a ginkgolide. Allograft rejection is therefore inhibited at a lower dose of the calcineurin inhibitor.
  • the combination drug therapy regimen described herein is based on the pharmacological action of compounds which when complexed to immunophilins suppress T cells with a gingkolide.
  • Immunophilin-binding compounds include calcineurin inhibitors include FK506 (and structurally-related macrolides) and CsA (and structurally-related undecapeptides) as well as rapamycin (and: structurally-related inhibitors of TOR).
  • Gingkolide compositions include extracts of ginkgo such as EGb761.
  • the gingkolide alone or a combination of an immunophilin-binding immunosuppressive agent and a gingkolide are used for post-transplant immunosuppression.
  • the combination of drugs has substantially lower toxicity than currently available drugs used for this purpose.
  • the dose of immunophilin-binding immunosuppressant required to achieve clinical immunosuppression is at least 5%, preferably at least 10%, preferably at least 25%, preferably at least 30%, more preferably at least 40%, and most preferably at least 50% less than that required for the same level of immunosuppression in the absence of a gingkolide.
  • Immunosuppression measured using methods known in the art, e.g., by detecting inhibition of T cell activation (indicated by IL-2 production or expression of activation-related cell surface markers) or by measuring length of allograft survival.
  • the combination drug therapy regimen is also useful as a postoperative cardioprotective agent and for long-term prophylaxis against cardiac hypertrophy.
  • a calcineurin inhibitor/ginkgolide combination drug offers a method for achieving immunosuppression sufficient to maintain transplanted tissue in a healthy, functional state with little or no side effects.
  • Advantages of the invention include improved outcomes to transplant surgery (both in terms of survival as well as drug-related morbidity), decreased need for secondary hospitalization, and reduced expenditure of health care costs for transplant recipents.
  • the cardioprotective effect of a calcineurin inhibitor in a calcineurin inhibitor/ginkolide combination is a 5 fold lower that that required to achieve the same degree of cardioprotection with the calcineurin inhibitor alone.
  • the synergistic effect in the combination therapy is applicable to immunosuppression. Treatment of cardiac hypertrophy
  • FK506 has been used for suppression of the onset and effects of cardiac hypertrophy in animals. However, sustained use of this drug at dosages required to prevent hypertrophy would be toxic and unsuitable for routine human use.
  • the biological pathway affected by FK506 is also responsive to gingkolides.
  • compositions and methods of the invention are useful for improved cardioprotection compared to the cardioprotective effect of immunophilin-binding compounds or calcineurin inhibitors alone.
  • the combination of the ginkgolide EGb 761 with FK506 was found to inhibit cardiac hypertrophy at 5-fold lower levels of FK506 than FK506 alone.
  • the coadministration strategy minimizes cardiac hypertrophy and decreases the incidence of ischemia/reperfusion related arrhythmias Immunosuppressive and cardioprotective compositions with reduced toxicity
  • the compositions described herein are based on the combined action of calcineurin inhibitory (also know as "TOR" inhibitory compounds) and one or more components of the gingko extract, Egb761.
  • Clinical administration of a calcineurin inhibitory substance, plus a ginkgolide- derived PAFR antagonist, phosphodiesterase inhibitor, or antioxidant reduces dosage of the calcineurin inhibitor required to achieve a desired immunosuppressive effect in mammals following organ transplantation.
  • Clinical administration of a calcineurin inhibitory substance plus a ginkgolide-derived PAFR antagonist, phosphodiesterase inhibitor, or antioxidant also positively affects cardiac functions in mammals via the same calcium-dependent signalling pathways which mediate immunosuppression.
  • a common biochemical pathway underlies the clinical conditions of graft rejection and cardiac dysfunction.
  • a rise in calcium in either T lymphocytes or cardiac myocytes, respectively, causes calmodulin-dependent activation of the phosphatase calcineurin.
  • Calcineurin activation results in processing of a class of transcription factor precursors, NFATn, which then translocate into the nucleus.
  • NFATn transcription factor precursors
  • T lymphocytes these factors cause gene expression resulting in immune activation and ultimately graft rejection.
  • cardiac tissue NFATn factors cause cellular changes which result in cardiac dysfunction.
  • Platelet Activating factor (PAFVCalcium/Calcineurin-dependent protection Calcium availability to calcineurin is reduced by supplementing treatment of a subject with a calcineurin inhibitor with one or more subcomponents of Ginkgo biloba (e.g., EGb761).
  • the gingkolide acts as an antagonist to the receptor for PAF, a potent bioactive phospholipid.
  • the PAFR when engaged by PAF, activates a signalling pathway causing a rise in intracellular calcium.
  • Gingkolide compounds inhibit PAF-mediated increase in cytoplasmic calcium, thereby augmenting calcineurin inhibition by a calcineurin inhibitor such as FK506 or CsA.
  • the low toxicity of ginkgohdes allows administration of dosages of gingkolide which substantially reduce dosage of calcineurin inhibitor required for immunosuppression (or cardioprotection) with little or no side effects.
  • Antioxidants stabilize cardiac membranes with respect to their ability to maintain compartmentalization of critical ionic species.
  • the antioxidant properties of Ginkgo biloba e.g., the terpene component of EGb761 has cardioprotective effects.
  • Antioxidants in EGb761 are also immunosuppressive by acting as scavengers of free radicals, thereby decreasing the degree of allograft-associated inflammatory damage.
  • EGb 761 is a standardized extract of dried leaves of Ginkgo biloba containing 24% ginkgo-flavonol glycosides, 6% terpene lactones (24/6) such as ginkgohdes A, B, C, J and bilobalide.
  • the PAFR antagonistic, phosphodiesterase inhibitory, and antioxidant effects of Egb761 confers clinical benefit, alone or when combined with a calcineurin inhibitor.
  • an immunosuppressive compound contains a calcineurin inhibitor with extract of Ginkgo biloba with a ratio of 27% ginkgo-flavonol glycosides, 7% terpene lactones (27/7), enriched in ginkgolide B.
  • Preparation of the gingkolide portion of the composition is known in the art, e.g., the method of Li, et al, 1997, Planta Medica. 63(6):563-5.
  • Coadministraton of a calcineurin inhibitor and gingkolide leads to improved post-transplant outcome
  • Calcineurin inhibitors e.g., FK506, were found to act synergistically with EGb761 to mediate cardioprotection. Similar mechanisms mediate post-transplant immunosuppression.
  • the immunological effects of Ginkgo biloba were evaluated.
  • the results indicate that a gingkolide, e.g., EGb761, causes a decrease in T lymphocyte activation as evidenced by suppression of CD25 and CD54 expression in activated cultures.
  • the gingkolide BN52021 was found to exhibit an anti-inflammatory effect.
  • the mechanism of the anti-inflammatory effect is distinct from the mechanism of immunosuppression of cyclosporine A.
  • the results indicate that combined administration of a immunophilin-binding immunosuppressive and ginkgolide leads to an increase in effective immunosuppression without a concomitant increase in toxicity.
  • the coadministration strategy is useful to treat inflammatory disorders, incuding transplant rejection.
  • compositions for immunosuppression and cardioprotection described herein include (1) a calcineurin inhibitor, (2) a PAFR receptor inhibitor, (3) a cell membrane stabilizer, and (4) a free oxygen radical scavenger.
  • Calcineurin inhibition results in suppression of T cell activation or alternatively suppression of cardiac pathology development.
  • PAFR inhibition, by ginkgolide components results in diminished intracellular calcium availability, causing suppression of T cell activation or alternatively suppression of cardiac pathology development.
  • Cardiac membrane stabilization by ginkgolide antioxidants results in improved compartmentalization of ionic species and suppression of cardiac pathology development.
  • Ginkgolide antioxidants scavenge oxygen radicals released by inflammatory leukocytes participating in graft rejection pathology - reducing inflammatory damage.
  • compositions are formulated into therapeutic compositions such as liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the particular indication targeted.
  • the compositions also include pharmaceutically acceptable vehicles or carriers. Suitable vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. Actual methods of preparing such compositions are known to those skilled in the art (e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 18th edition, 1990).
  • compositions are administered using conventional modes of delivery including intravenous, intraperitoneal, oral or subcutaneous administration.
  • compositions are locally administered, e.g., to the site of an allografted tissue or a site of inflammation
  • Immunophilin-binding immunosuppressive agents are administered according to methods known in the art. Therapeutically effective doses are known. For example, treatment with FK506 to prevent graft rejection is conducted so as to maintain trough whole blood levels in the therapeutic range of 0.1 -1000 ng/ml (e.g., 5-20 ng/ml).
  • FK506 in the range of about 0.1 - 5.0 mg FK506 per kg of body weight posttransplant, with dosage decreased to as low as 0.76 mg/kg for some categories of patients
  • dosage decreased to as low as 0.76 mg/kg for some categories of patients
  • treatment with this drug even at low doses (0.1 mg/kg or less), is effective in maintaining blood levels in the vicinity of 10 ng/ml - resulting in greater than 1 year graft survival for >70% of those treated.
  • FK506 produces chronic side effects including: hypertension, tremor, diabetes mellitus, diarrhoea and nephrotoxicity in a significant fraction of patients.
  • the invention provides the advantage of reducing the effective dosage of FK506 or CsA by coadministering a gingkolide.
  • the combination of drugs augments CsA-mediated effects (while decreasing toxicity), and allows a reduction of FK506 dosage by a factor of 3-5 below what is currently perscribed with commensurate reductions in toxic side effects.
  • the dosages of immunophilin-binding drug (and of gingkolide) may vary depending on the severity and course of the disease, the patient's health and response to treatment, and the judgment of the treating physician.
  • the gingkolide and calcineurin inhibitor are administered simultaneously or sequentially.
  • a calcineurin inhibitor is administered at a dosage of 0.1-12.0 mg/kg/day, more preferably about 0.5-6.0 mg/kg/day, and more preferably about 1.0-3.0 mg/kg/day.
  • the selected dose is administered to a mammal in need of immunosuppression from 1-6 times daily, and is administered topically, orally, rectally, by injection, or continuously by infusion.
  • Oral dosage units for human administration preferably contain from 0.1 to 500 mg of each active compound.
  • Oral administration which uses lower dosages of a calcineurin inhibitor is preferred. Parenteral administration, at higher dosages, may also be used.
  • Gingkolide compositions are administered in doses of 0.1 mg/kg/day to 1000 mg/kg/day. (e.g., 10 mg/kg/day - 60 mg/kg/day). Routes of administration are comparable to those used for immunophilin-binding compounds such as calcineurin inhibitors.
  • the compositions are administered before or after transplantation of an allograft.
  • the allografted tissue is bathed in a solution of the immunosuppressive composition and/or the tissue is perfused with such a solution.
  • the methods are useful for the treatment of recipients of allogeneic cells or solid organs, e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants as well as those suffering from or at risk of developing acute rejection; hyperacute rejection, e.g., as associated with xenograft rejection; and chronic rejection, e.g., as associated with graft-vessel disease.
  • the compositions are used to treat or prevent the development of graft-versus-host disease, such as that which may occur following bone marrow transplantation.
  • the immunosuppressive compositions are useful to treat or prevent autoimmune disease and of inflammatory conditions such as asthma, arthritis (e.g., rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
  • autoimmune disease e.g., rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans
  • rheumatic diseases e.g., rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans
  • Specific auto-immune diseases for which the compositions of the invention may be employed include, autoimmune hematological disorders (including e.g.
  • hemolytic anaemia aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia
  • systemic lupus erythematosus polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven- Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g.
  • ulcerative colitis and Crohn's disease endocrine ophthalmopathy
  • Graves disease sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.
  • compositions and methods are suitatble for treatment of adult, newborn and fetal mammals. Treatment encompasses the prevention of and adverse clinical condition, e.g., transplant rejection), and the reduction or elimination of symptoms of a disease or adverse clinical condition.
  • An immunosuppressive composition refers to any composition that suppresses or prevents an undesired immune response, e.g., prevent the immune system's rejection of a transplanted organ. Preferably, the composition reduces the activity of T cells.
  • the combination drug therapy described herein utilizes an immunophilin-binding immunosuppressive agent (e.g., CsA, FK506, or rapamycin) and a gingkolide composition, which contains PAFR antagonist activity and antioxidant activity.
  • an immunophilin-binding immunosuppressive agent e.g., CsA, FK506, or rapamycin
  • a gingkolide composition which contains PAFR antagonist activity and antioxidant activity.
  • the gingkolide compositions contains at least two antioxidant components of Gingko biloba, e.g., GB, GC, GJ, or GM, rather than one component such as GM alone.
  • the gingkolide composition is Egb761 contains several antioxidant components of Gingko biloba in addition to a component with PAFR antagonist activity.
  • EGb761 contains a full range of antioxidants and PAFR antagonists produced by leaves of the plant.
  • EGb761 provides a higher degree of membrane stabilization (due to oxygen radical absorption), resulting in improved regulation of ion flow (especially calcium) and less free radical-mediated tissue damage than would be expected if BN52021 were the only ginkgolide component.
  • one gingkolide GB (BN52021) has been shown to minimize the alteration of renal function induced by CsA
  • the present compositions and methods are distinguished over existing methods in that the ginkgolide composition is administered at a dose that is immunosuppressive (e.g., inhibits T cell activation).
  • Example 1 Suppression of T cell activity by Egb761
  • BN52021 The immunosuppressive activity of BN52021 was compared with that of CsA.
  • BN52021 is a component of EGb761.
  • BN52021 has PAFR antagonist activity.
  • the immunomodulatory effect of BN50521 was examined, and in vitro immune response parameters in human PBMC stimulated with EGb761 were compared to positive control stimulants such as PHA or PMA/I.
  • BN52021 was incubated with the nonadherent fraction of PBMC cultures (i.e. primarily T and B lymphocytes).
  • Example 2 Combination therapy for asthma using a gingkolide and a calcineurin inhibitor
  • ginkgolide B BN52021
  • Standard methods e.g., 2 channel flow cytometric analysis of activation-associated cell surface antigens, or ELISA assays, were used to detect cytokines known to be expressed by PBMC during T] or T 2 immunological activation.
  • BN52021 is an anti-inflammatory extract of Ginkgo biloba and has been used therapeutically.
  • BN52021 inhibits PAF, which is important in the pathogenesis of asthma.
  • the data described herein indicate that gingkolides synergize with CsA to inhibit pathogenic immune activation in asthmatics.
  • BN52021 and CsA (l ⁇ M/L each) on activation of PBMC of asthmatic patients were measured.
  • the cells were stimulated by phorbol myristate acetate (PMA) and calcium ionophore (IOM) and contacted with the gingkolide and/or CsA.
  • PMA phorbol myristate acetate
  • IOM calcium ionophore
  • Inhibition of production of the cytokines IL-4 and IL-5 by BN52021 was insignificant compared to CsA.
  • BN52021 significantly reversed the increase in activation- associated CD45RA expression, with a trend towards decreased expression of HLA-DR. Lymphocyte activation markers were not significantly altered by CsA.
  • the mechanism of immunosuppression of gingkolides is different from that of calcineurin inhibitors, and coadministration of a gingkolide and a calcineurin inhibitor results in at least an additive immunosuppressive effect. In some cases, the effect is synergistic.
  • PBMC peripheral blood mononuclear cells
  • AIM-V medium Gibco BRL, Gaithersburg, MD
  • PMA phorbol 12-myristate 13-acetate
  • IOM l ⁇ M ionomycin
  • Cytokine expression (IL-4 and IL-5) was evaluated in culture supernatants by enzyme-linked immunoabsorption assay (Amersham North America, Illinois, USA). The detection range was 10-400 pg/ml and 7.8-500 pg/ml respectively. Colorimetric changes proportional to supernatant cytokine concentration were measured using a model 2550 EIA reader (Bio-Rad Laboratories, Hercules CA. USA). All assays were performed in duplicate. Flow cytometric analysis
  • Two-color flow cytometry was conducted using a Coulter Epics Profile II flow cytometer (Coulter Scientific, Hialeah, FL, USA).
  • Isotypic controls for the monoclonal antibodies (mAb) used to detect antigens of interest were established for each cell preparation. Positive analysis regions for cells expressing specific surface antigens were set against isotypic controls and specific binding of fluorophore-conjugated mAb was analyzed by cytofluorography according to standard methods. Lymphocyte subpopulations were identified by position on forward and side scatter plots and live-gated. Isotype matched antibodies were utilized to control for nonspecific fluorescence.
  • Peripheral blood mononuclear cells from asthmatic subjects were labeled with fluorophore-conjugated, nonspecific antibody, chain-matched with the antibody to be used for a particular assay. Background values for antibodies used in assays were based on fluorescence of non-specific antibodies. Monoclonal antibodies specific for human CD25, CD45RA, CD54, HLA-DR were purchased from Dakopatts, A/S, Glostrup, Denmark. Expression of each antigen is reported as percentage cells positive for a particular surface marker plus or minus standard error. Statistical analysis
  • Fig. 1 and Table 2 show the cytokine levels in culture supernatants produced by cells under each stimulation condition.
  • BN52021 had no statistically significant effect on expression of either cytokine.
  • Table 2 The data shown Table 2 was obtained using cultures of 2 x 10 ⁇ human PBMC, which were isolated from venous blood and stimulated 24 hours with media, 20 nM PMA + 1.0 ⁇ M ionomycin (PMA/I), 1.0 ⁇ M cyclosporine A + PMA/IOM, or l ⁇ M ginkgolide BN52021 + PMA. Expression of interleukins 4 and 5 were measured in PBMC culture supernatents by antibody capture ELISA.
  • Table 2 IL-4 and IL-5 expression by peripheral blood mononuclear cells and lymphocyte surface antigen expression in asthma patients
  • IL-5 (pg/ml) 92.5 ⁇ 13.2 440.5 ⁇ 72.2* ⁇ 96.2 ⁇ 12.9*** 374 ⁇ 105 % CD25 8.07 ⁇ 3.5 11.8 ⁇ 3.5 9.0 ⁇ 2.7 7.1 ⁇ 2.0
  • BN52021 showed different effects on cytokine production and surface antigen expression by PBMC from asthma patients stimulated with PMA and inonomycin. CsA completely inhibited IL-4 and IL-5 production whereas BN52021 had very little effect. BN52021, but not CsA, significantly reduced CD45RA and showed a trend towards reduced expression of HLADR. CD25, CD54 were not significantly changed with either agent. The profound effect of CsA on IL-4 and IL-5 expression is mediated by its direct inhibition of calcineurin. BN52021 fails to effectively suppress calmodulin/calcineurin dependent expression of IL-4 and IL-5.
  • the potent PAF receptor antagonist, BN52021 has been shown to have beneficial clinical effects on aspects of asthma pathogenesis mediated by PAF.
  • the mechanism by which it modulates surface antigen expression during lymphocyte activation is likely due to selective elimination of CD45RA + cells or a shift in the equilibrium towards CD45RO + lymphocytes.
  • Certain states of lymphocyte activation may be associated with enhanced dual expression of CD45RO and RA, and the reduction of RA expression represents a suppressive immunomodulatory effect.
  • Circulating CD45RA + /CD45RO +/ HLADR+ cells which are increased in atopic asthma area transitional cellular phenotype, leading ultimately to a pathogenic T cell.
  • the data indicate that, by its inhibition of CD45RA and HLA-DR, BN52021 exerts a clinical benefit by suppression of the development of these cells.
  • calcineurin acts on the cytoplasmic precursor of the transcription factor NFAT 3 , to allow its translocation into the nucleus, where it interacts with the cardiac-restricted, zinc finger transcription factor GATA4, eventually giving rise to cardiac hypertrophy.
  • FK506 dose-dependently reduced the incidence of reperfusion-induced total (irreversible plus reversible) NF from a value of 92% for untreated animals, to: 92% ( ⁇ S), 83% ( ⁇ S), 67% ( ⁇ S), 33% (p ⁇ 0.05), and 25% (p ⁇ 0.05), for doses of 1-40 mg/kg/day respectively, with effects on incidence of NT showing the same pattern.
  • FK506 between 20 and 40 mg/kg/day also resulted in significant recovery of postischemic cardiac function.
  • rats were treated with or EGb761 alone or with the combination of FK506.
  • the synergistic activity of FK506 and a gingkolide allows therapy with FK506 for cardioprotection as well as immunosuppression for transplant recipients and individuals suffering from autoimmune disease, at lower doses of FK506 than are currently used. Animals
  • Rats were anesthetized with intraperitoneal pentobarbital sodium (60 mg/kg body weight) and then given intravenous heparin (500 IU/kg). After thoracotomy, the heart was excised and placed in ice cold perfusion buffer. Immediately after preparation, the aorta was cannulated, and the heart was perfused according to Langendorf method for a 5-min washout period at a constant perfusion pressure equivalent to 100 cm of water (10 kPa).
  • the perfusion medium consisted of a modified Krebs-Henseleit bicarbonate buffer: 118 mM ⁇ aCl, 4.7 mM KC1, 1.7 mM CaCl 2 , 25 mM ⁇ aHC0 3 , 0.36 mM KH 2 P0 4 , 1.2 mM MgS0 4 , and 10 mM glucose.
  • the left atrium was cannulated and the Langendorff system was switched to the working mode with a left atrial filling pressure of 17 cm of buffer (1.7 kPa) and aortic afterload pressure of 100 cm (10 kPa) of buffer.
  • Aortic flow was measured by a calibrated rotameter, and coronary flow rate was measured by a timed collection of the coronary perfusate that dripped from the heart. Induction of ischemia and reperfusion
  • ECG epicardial ECG was recorded by a polygraph throughout the experimental period by two silver electrodes attached directly to the heart. ECGs were analyzed to determine the incidence of ventricular fibrillation (NF) and ventricular tachycardia (NT) and whether NF was non-sustained (spontaneously reverting to regular rhythm) or sustained (persisting through the first 3 min of reperfusion). After 3 min of ventricular fibrillation (sustained NF) hearts were defibrillated and myocardial function was recorded. The heart was considered to be in NF if an irregular undulating baseline was apparent on the ECG.
  • NF ventricular fibrillation
  • NT ventricular tachycardia
  • NT was defined as 5 or more consecutive premature ventricular complexes; and this classification included repetitive monomorphic NT, which is difficult to dissociate from rapid NT. In each instance, NT spontaneously switched to sinus rhythm or NF, therefore NT was considered non- sustained. The heart was considered to be in sinus rhythm if normal sinus complexes occurring in a regular rhythm were apparent on the ECG. Before ischemia and during reperfusion, heart rate (HR), coronary flow (CF) and aortic flow (AF) rates were registered.
  • HR heart rate
  • CF coronary flow
  • AF aortic flow
  • LNDP Left ventricular developed pressure
  • the preischemic values of HR, CF, AF, LVDP and +LVdP/dt max were 305 ⁇ 8 beats/min., 27.3 ⁇ 0.8 ml/min., 49.9 ⁇ 1.4 ml/min., 18.2 ⁇ 0.3 kPa and 807 ⁇ 21 kPa/s respectively. No significant changes were observed in these values as a result of FK506 treatment.
  • Table 3 shows the absolute values for postischemic cardiac function in the drug-free control and FK 506 treated groups.
  • CF, AF, LVDP, and LVdP/dt max was observed in the groups treated with 20 and 40 mg/kg of FK 506, respectively.
  • Heart rate did not show a significant change in the treated groups in comparison with the drug-free control values, either before the induction of ischemia or during reperfusion.
  • Figs. 4A-B show that neither 25 mg/kg of EGb 761 nor 1 and 5 mg/kg of FK 506 significantly reduced the incidence (%) of reperfusion-induced arrhythmias.
  • the combination of 25 mg/kg of EGb 761 with 1 or 5 mg/kg of FK 506 resulted in a significant reduction in the incidence of reperfusion-induced VF (Fig. 4A) and VT (Fig. 4B).
  • the coadministration of 25 mg/kg EGb 761 with 1 and 5 mg/kg of FK 506 Fig.
  • Table 4 shows that cardiac function was not significantly changed in the groups treated with a single interventions during reperfusion.
  • Heart rate was not significantly changed in the combination group either before the introduction of ischemia or during reperfusion (Table 4).
  • the results described herein support a role for FK506 as an antiarrhythmic agent and additionally demonstrate its capacity to improve cardiac function.
  • a dose-dependent improvement in cardiac function (Table 3) and inhibition of postischemic arrhythmias (Figs.3A-B) resulted from pretreatment of rats with FK506. It is likely that this effect is the result of FK506-mediated blockage of events downstream of calcineurin/NFAT3/GATA4.
  • a calcineurin-independent property of FK506 may also play a role in cardioprotection.
  • FK506 is observed to form a complex with FKBP12, a ubiquitously expressed 12 kDa immunophilin protein, which subsequently binds to calcineurin in the presence of FK506, inhibiting its ability to dephosphorylate cytoplasmic NFAT 3 and blocking NFAT3 -dependent gene expression.
  • FKBP12 has been demonstrated to be a regulatory structural component ofthe ryanodine receptor intracellular calcium release channel (RyR). Calcium channels composed exclusively of RyR (with no associated FKBP12) manifest altered calcium flux across the sarcoplasmic membrane; moreover, channels incorporating FK506-bound FKBP12 exhibit abnormal calcium gating properties.
  • FKBP12 a major role for FKBP12 is to modulate the calcium flux through the RyR channel complex. This function is disrupted if FK506 is additionally incorporated, causing a reversal ofthe channel-stabilizing effects of FKBP12, producing effects which include increased channel sensitivity to channel-opening ligands such as caffeine, elevated calcium flow and leakage ofthe ion across sarcoplasmic reticulum.
  • FK506 is additionally incorporated, causing a reversal ofthe channel-stabilizing effects of FKBP12, producing effects which include increased channel sensitivity to channel-opening ligands such as caffeine, elevated calcium flow and leakage ofthe ion across sarcoplasmic reticulum.
  • clinical use of FK506 in humans is at dosage levels too low to bind significant amounts of FKBP, the observed effects occurred at relatively high, perhaps toxic, doses of FK506, with no effects noted on VF, VT or hemodynamic recovery below 20 mg/kg.
  • FK506 may possess a mode of pharmacological action separate from calcineurin inhibition (which is known to occur efficiently at dosages in the range of 0.15 mg/kg). It is likely that the increased leak of calcium occurring in the presence of FK506 alter normal pathways to cardiac excitation and lead to arrhythmogenesis. However, based on the efficient inhibition of calcineurin phosphatase at relatively low doses, it is likely that the effects are the result of FK506 interaction with Ca " " " " channel proteins such as FKBP12.
  • FK506 Combining FK506 with other treatments which lower its dosage requirement without diminishing its cardioprotective properties allows clinical use of FK506 in prevention and therapy of cardiac disorders.
  • the highest dosage ofthe ginkgolide was 25 mg/kg, which did not result in significant decreases in either VF or VT.
  • FK506 dosages between 1-5 mg/kg failed to affect these parameters.
  • Combined treatment with both drugs synergistically and dose-responsively reduced the incidence of postischemic arrhythmias and additionally resulted in significant improvements in cardiac function.
  • the molecular mechanisms contributing to these effects include diminished levels of oxygen radical-induced damage to cardiomyocyte membranes, resulting from the demonstrated antioxidant properties of EGb 761, contributing to restoration of stable compartmentalization and transmembrane flow of Na + , K + , Ca 2+ and Mg 2+ .
  • the data indicate that development of cardiac hypertrophy is prevented by administration of an immunophilin-binding immunosuppressive agent and a gingkolide.
  • the combination allows subtoxic dosage of an immunophilin-binding composition, e.g., FK506, by coadministration of a ginkgolide.
  • Example 4 Effect of EGb761 and cyclosporin on PHA-induced expression ofthe lymphocyte surface activation antigens CD25 by peripheral blood mononuclear cells in vitro Combined treatment with both ginkgo extract and cyclosporin synergistically inhibits immune activation in human tissue.
  • PBMC peripheral blood mononuclear cells
  • the data shown in Table 5 indicate that the gingkolide preparation, Egb761, alone suppresses immune activation by human leukocytes. Cyclosporin further reduces expression of CD25.
  • the effect ofthe gingkolide and cyclosporin is more than additive; the addition of cyclosporin demonstrates a synergistic immunosuppressive effect ofthe combination of these drugs.
  • the results also demonstrate the advantage of using this particular approach to screen a large number of candidate preparations for immunosuppressive potential. The assay is easily performed and allows a large number of samples to be processed simultaneously.
  • Immunosuppressive agents are identified by an immune cell population, e.g., PBMC, or a T cell line, with candidate ginkgolide compound and measuring T cell activation.
  • the cells are activated in culture, e.g., by culturing the cells in the presence of an immunostimulatory compound such as phytohemagglutinin (PHA).
  • PHA phytohemagglutinin
  • a decrease in T cell activation in the presence ofthe compound compared to the level in the absence ofthe compound indicates that the compound is an immunosuppressive agent.
  • Immune cell activation is measured using known methods, e.g., cell proliferation, expression of cell surface markers such as CD25, or elaboration of cytokines such as IL-2.
  • a method of identifying identifying a syngergistic combination of immunosuppressive compounds is carried out similarly activating cultures of immune cells (a) in the presence an immunophilin- binding compound, (b) in the presence of a candidate ginkgolide compound; and (c) in the presence of both an immunophilin-binding compound and a candidate ginkgolide compound. Immune activation in each sample is measured as described above. A greater than additive decrease in T cell activation detected in (c) compared to that detected in (a) and (b) indicates that the ginkgolide and immunophilin-binding compound tested are synergistically immunosuppressive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à une composition contenant un composé de fixation d'immunophiline et un composé de ginkgolide, à des procédés permettant d'induire l'immunosuppression et à des procédés de criblage de composés de ginkgolide immunosuppresseurs. Le composé de ginkgolide est choisi dans le groupe constitué par un inhibiteur de phosphodiestérase, un antagoniste du facteur d'activation des plaquettes (PAFR) et un piégeur de radicaux libres.
PCT/US2001/014718 2000-05-08 2001-05-08 Compositions immunosuppressives WO2001085206A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01935128A EP1299119A2 (fr) 2000-05-08 2001-05-08 Compositions immunosuppressives contenants un compose de liaison d'immunophilinee et un compose ginkgolide
AU2001261248A AU2001261248A1 (en) 2000-05-08 2001-05-08 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
JP2001581859A JP2004510694A (ja) 2000-05-08 2001-05-08 免疫抑制性組成物
CA002408889A CA2408889A1 (fr) 2000-05-08 2001-05-08 Compositions immunosuppressives
US10/275,996 US20040091477A1 (en) 2001-05-08 2001-05-08 Immunosuppresive compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20311000P 2000-05-08 2000-05-08
US60/203,110 2000-05-08

Publications (2)

Publication Number Publication Date
WO2001085206A2 true WO2001085206A2 (fr) 2001-11-15
WO2001085206A3 WO2001085206A3 (fr) 2002-10-24

Family

ID=22752547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014718 WO2001085206A2 (fr) 2000-05-08 2001-05-08 Compositions immunosuppressives

Country Status (5)

Country Link
EP (1) EP1299119A2 (fr)
JP (1) JP2004510694A (fr)
AU (1) AU2001261248A1 (fr)
CA (1) CA2408889A1 (fr)
WO (1) WO2001085206A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055480A1 (fr) * 2001-12-21 2003-07-10 Pharmaconsult Oy Produits a utiliser dans une therapie immunosuppressive et renfermant de l'acide lipoique et un inhibiteur de la calcineurine
WO2003061572A2 (fr) * 2002-01-16 2003-07-31 David Haines Formulations anti-inflammatoires
WO2005097164A2 (fr) * 2004-04-08 2005-10-20 Novartis Ag Nim811 utilise dansla prevention ou le traitement de l'ischemie cerebrale et de lesions cerebrales et de la moelle epiniere
EP1599212A2 (fr) * 2003-02-14 2005-11-30 Combinatorx, Incorporated Polytherapie servant au traitement de troubles immuno-inflammatoires

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924785A (en) * 2007-07-31 2009-06-16 Limerick Biopharma Inc Phosphorylated pyrone analogs and methods
JP6022548B2 (ja) * 2011-04-28 2016-11-09 セルジーン コーポレイション Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
JP2015000001A (ja) * 2013-06-12 2015-01-05 株式会社明治 過敏性腸症候群モデル動物の作成方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B.PIGNOL E.A.: "Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection" TRANSPLANTATION PROCEEDINGS, vol. 20, no. sup. 2, 1988, pages 259-265, XP008004475 *
C.BAGNIS E.A.: "Prevention of cyclosporine nephrotoxicity with a PAF-antagonist." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 4, no. 3, 1993, page 749 XP008004472 *
C.TOUVAY E.A.: "Effect of cyclosporin A and the platelet-activating factor (PAF) antagonist, BN52021, on PAF- and antigen- induced bronchoconstriction in the guinea-pig" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 163, no. 1, 1989, pages 118-123, XP001073938 *
D.D.HAINES E.A.: "Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts" JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 35, no. 1, 2000, pages 37-44, XP008004470 *
E.P.PIROTZKY E.A.: "Protection of ciclosporin-induced nephrotoxicity in the rat by the ginkgolide mixture, BN 52063" NEW TRENDS IN LIPID MEDIATORS RESEARCH, vol. 2, 1988, pages 181-184, XP008004473 *
J.C.MUINO E.A.: "Prolongation of rabbit skin allograft survival with immunosuppression and specific antagonist of platelet-activating factor" TRANSPLANTATION PROCEEDINGS, vol. 20, no. sup. 1, 1987, pages 313-315, XP008004480 *
M.L.FOEGH E.A.: "Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor" TRANSPLANTATION (BALTIMORE), vol. 42, no. 1, 1986, pages 86-88, XP008004474 *
M.L.FOEGH E.A.: "Synergistic effect of a platelet activating factor antagonist with azathioprine and cyclosporin A in allograft survival" 1987 , JOHN WILEY & SONS , CHICHESTER, UK XP008004478 page 343 page 344 *
P.H.BACH E.A.: "Nephrotoxicity: mechanisms, early diagnosis and therapeutic management; fourth international symposium on nephrotoxicity, Guilford, UK, 1989" 1989 , MARCEL DEKKER INC. , NEW YORK,USA XP008004471 page 187 -page 191 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055480A1 (fr) * 2001-12-21 2003-07-10 Pharmaconsult Oy Produits a utiliser dans une therapie immunosuppressive et renfermant de l'acide lipoique et un inhibiteur de la calcineurine
WO2003061572A2 (fr) * 2002-01-16 2003-07-31 David Haines Formulations anti-inflammatoires
WO2003061572A3 (fr) * 2002-01-16 2004-05-13 David Haines Formulations anti-inflammatoires
EP1599212A2 (fr) * 2003-02-14 2005-11-30 Combinatorx, Incorporated Polytherapie servant au traitement de troubles immuno-inflammatoires
EP1599212A4 (fr) * 2003-02-14 2006-02-08 Combinatorx Inc Polytherapie servant au traitement de troubles immuno-inflammatoires
WO2005097164A2 (fr) * 2004-04-08 2005-10-20 Novartis Ag Nim811 utilise dansla prevention ou le traitement de l'ischemie cerebrale et de lesions cerebrales et de la moelle epiniere
WO2005097164A3 (fr) * 2004-04-08 2006-06-01 Novartis Ag Nim811 utilise dansla prevention ou le traitement de l'ischemie cerebrale et de lesions cerebrales et de la moelle epiniere

Also Published As

Publication number Publication date
JP2004510694A (ja) 2004-04-08
CA2408889A1 (fr) 2001-11-15
EP1299119A2 (fr) 2003-04-09
AU2001261248A1 (en) 2001-11-20
WO2001085206A3 (fr) 2002-10-24

Similar Documents

Publication Publication Date Title
CA2261666C (fr) Compositions pharmaceutiques utiles dans le traitement de rejets de greffe, d'etats auto-immuns ou inflammatoires, comprenant de la cyclosporine a et de la 40-0-(2-hydroxyethyl)-rapamycine
US5843452A (en) Immunotherapy composition and method
US20040091477A1 (en) Immunosuppresive compositions
WO2001085206A2 (fr) Compositions immunosuppressives
Kirk et al. Cyclosporine-associated hypertension in cardiopulmonary transplantation: The beneficial effect of nifedipine on renal function
US5759550A (en) Method for suppressing xenograft rejection
Roilides et al. In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus
MONTGOMERY et al. Didemnin B–An immunosuppressive cyclic peptide that stimulates murine hemagglutinating antibody responses and induces leukocytosis in vivo
Bertelmann et al. Corneal allograft rejection: current understanding: 2. Clinical implications
Jiang et al. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival
US20030170328A1 (en) Anti-inflammatory formulations
Quesniaux et al. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T-and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral® or with RAD
AU2007200012A1 (en) Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
Kay Immunosuppressive agents in chronic severe asthma
JP7549287B2 (ja) 植物由来アルカロイドを含有する医薬組成物
EP1305047B1 (fr) Antagonistes non peptidiques des recepteurs ccr1 combines a la cyclosporine a en vue de combattre une reaction de rejet apres une transplantation cardiaque
de Rie et al. Cyclosporine immunotherapy
US5801144A (en) Use of a compound for the manufacture of a medicament for the treatment of HIV infection
Darlametsos et al. Effect of Ketanserine in Cyclosporine-lnduced Renal Dysfunction in Rats
Locatelli et al. Sirolimus-related toxicity in stem cell transplantation
Ezeamuzie Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506
AU2001278073A1 (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
Japanese FK506 Study Group Japanese study of kidney transplantation: 1. Results of early phase II study
De Mattos et al. Cyclosporine nephropathy: clinical, histological, and functional aspects
Thomson et al. Rejection, the Immune Response, and the Influence of Cyclosporin A

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2408889

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001261248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001935128

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935128

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275996

Country of ref document: US